Key result
Thrombosis in patients with cancer is associated with poorer overall survival rates, necessitating careful selection of ambulatory patients for thromboprophylaxis.
Why the study?
Which ambulatory patients with cancer might benefit from thromboprophylaxis to prevent venous thromboembolism?
Which ambulatory patients with cancer might benefit from thromboprophylaxis to prevent venous thromboembolism?
This review provides guidance on identifying ambulatory cancer patients who may benefit from VTE prophylaxis.
Supports careful VTE prophylaxis selection in ambulatory cancer patients; leaves open optimal criteria for prospective validation.
Patients with cancer are at increased risk for thrombosis, and those with thrombi have poorer overall survival rates than those without. The author summarizes available data and provides guidance for determining which patients might benefit from thromboprophylaxis.
No takes yet. Share an insight, caveat, or question.
Jean M. Connors (2014) studied this question. Thrombosis in patients with cancer is associated with poorer overall survival rates, necessitating careful selection of ambulatory patients for thromboprophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: